Ambit Announces Participation At Leerink Global Healthcare Conference - Action News 5 - Memphis, Tennessee

Ambit Announces Participation At Leerink Global Healthcare Conference

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Ambit Biosciences

SAN DIEGO, Feb. 4, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Leerink Global Healthcare Conference to be held at the Waldorf Astoria in New York City, February 12-13, 2014.

Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, quizartinib, at 8:00 a.m. ET on Wednesday, February 12, 2014.  The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com.  An audio replay will be available until March 1, 2014 following the initial presentation webcast. 

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Ambit Contacts:


Marcy Graham

Andrew McDonald, Ph.D.

Executive Director, Investor Relations & Corp Comm

LifeSci Advisors, LLC

Ambit Biosciences, Inc.

Founding Partner

858-334-2125

646-597-6987

mgraham@ambitbio.com

andrew@lifesciadvisors.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow